22-20982334-T-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 1P and 1B. PP5BP4
The NM_006767.4(LZTR1):c.-38T>A variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000295 in 1,493,790 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000031 ( 0 hom. )
Consequence
LZTR1
NM_006767.4 5_prime_UTR
NM_006767.4 5_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.226
Genes affected
LZTR1 (HGNC:6742): (leucine zipper like post translational regulator 1) This gene encodes a member of the BTB-kelch superfamily. Initially described as a putative transcriptional regulator based on weak homology to members of the basic leucine zipper-like family, the encoded protein subsequently has been shown to localize exclusively to the Golgi network where it may help stabilize the Gogli complex. Deletion of this gene may be associated with DiGeorge syndrome. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PP5
Variant 22-20982334-T-A is Pathogenic according to our data. Variant chr22-20982334-T-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 549752.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=3, Pathogenic=1, Uncertain_significance=2}.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.75). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LZTR1 | NM_006767.4 | c.-38T>A | 5_prime_UTR_variant | 1/21 | ENST00000646124.2 | NP_006758.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LZTR1 | ENST00000646124.2 | c.-38T>A | 5_prime_UTR_variant | 1/21 | NM_006767.4 | ENSP00000496779 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152126Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
152126
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000802 AC: 1AN: 124616Hom.: 0 AF XY: 0.0000147 AC XY: 1AN XY: 67828
GnomAD3 exomes
AF:
AC:
1
AN:
124616
Hom.:
AF XY:
AC XY:
1
AN XY:
67828
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000313 AC: 42AN: 1341664Hom.: 0 Cov.: 29 AF XY: 0.0000242 AC XY: 16AN XY: 660042
GnomAD4 exome
AF:
AC:
42
AN:
1341664
Hom.:
Cov.:
29
AF XY:
AC XY:
16
AN XY:
660042
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152126Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74314
GnomAD4 genome
AF:
AC:
2
AN:
152126
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
74314
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:4Uncertain:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 26, 2022 | Published functional studies demonstrate an approximately 20% reduction in activity compared to the wildtype. Additionally, models suggest that the variant creates a new ATG start site upstream of the endogenous start site but this was not tested functionally (Pagnamenta et al., 2019); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30859559) - |
Noonan syndrome 2;C4225280:Noonan syndrome 10 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Apr 07, 2021 | ACMG classification criteria: PS4 supporting, PM2, PM3 strong - |
Noonan syndrome 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Genomic Medicine Theme, NIHR Oxford Biomedical Research Centre, University of Oxford | Jan 30, 2019 | As well as lying in trans with a pathogenic allele and co-segregating with disease in the pedigree, the effect of the 5’-UTR variant c.-38T>A on the expression of LZTR1 was further investigated using a dual luciferase reporter assay, as previously described (Calvo et al 2009 PMID: 19372376). The ratio of renilla to firefly luciferase was consistently reduced to 77-85% for the mutant 5’-UTR in comparison to the WT. - |
Noonan syndrome 2;C3810283:LZTR1-related schwannomatosis;C4225280:Noonan syndrome 10 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 02, 2022 | - - |
LZTR1-related schwannomatosis Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 23, 2023 | - - |
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 12, 2023 | The c.-38T>A variant is located in the 5' untranslated region (5’ UTR) of the LZTR1 gene. This variant results from a T to A substitution 38 bases upstream from the first translated codon and introduces a possible alternative, out-of-frame initiation codon. This alteration has been detected in trans with LZTR1 c.1311G>A p.W437* in two siblings with suspected autosomal recessive Noonan Syndrome; an unaffected sibling did not carry both variants (Pagnamenta AT et al. Clin. Genet., 2019 Jun;95:693-703). An in vitro functional assay indicated that this variant results in a partial reduction in protein expression; however, the clinical relevance of the observed level of reduction is unclear (Pagnamenta AT et al. Clin. Genet., 2019 Jun;95:693-703). This nucleotide position is not well conserved in available vertebrate species. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at